Home › Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines
 

Keywords :   


Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines

2013-06-12 14:00:00| Merck.com - Product News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Associations (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors such as JANUVIA (sitagliptin). Language:  English Contact HTML:  MerckMedia:Pam Eisele(267) 664-0282orKim Hamilton(908) 391-0131orInvestor:Carol Ferguson(908) 423-4465 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: other profile review safety

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
More »